Overview

* VYNE Q3 net loss decreases compared to last year

* Company progressing with strategic review to maximize shareholder value

Outlook

* VYNE is conducting a strategic review to explore options like partnerships or mergers

* Company expects cash runway to last into the first half of 2027

* VYNE is conducting a 12-week toxicology study for VYN202 to lift a clinical hold

Result Drivers

* STRATEGIC REVIEW - Co is evaluating strategic alternatives to maximize shareholder value, including potential partnerships and transactions

* COST REDUCTIONS - Co implemented cost reductions to extend cash runway into first half of 2027

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $169,000

Revenue

Q3 Net -$7.28

Income mln

Q3 EPS -$0.17

from

Cont Ops

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Vyne Therapeutics Inc ( VYNE ) is $3.25, about 89.6% above its November 5 closing price of $0.34

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)